不适合移植的大 B 细胞淋巴瘤二线使用 axicabtagene ciloleucel:ALYCANTE 最终分析
Second-line axicabtagene ciloleucel in large B-cell lymphoma ineligible for transplantation: ALYCANTE final analysis.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:GPCR signaling contributes to immune characteristics of microenvironment and process of EBV-induced lymphomagenesis.
GPCR signaling contributes to immune characteristics of microenvironment and process of EBV-induced lymphomagenesis.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
EBV 是多种癌症的致癌驱动因素。然而,病毒-癌症免疫相互作用在疾病发病机制中的潜在机制在很大程度上仍不清楚。在此,我们报道了自然杀伤/T细胞淋巴瘤(NKTCL)的首个全面蛋白质基因组学特征描述,NKTCL 是研究 EBV 诱导淋巴瘤发生的代表性疾病模型,整合了基因组学、转录组学和深度蛋白质组学数据。
我们对 NKTCL 的多组学分析揭示,EBV 基因模式与免疫相关致癌信号传导相关。单细胞转录组进一步将肿瘤微环境描述为免疫炎症型、免疫缺陷型和免疫荒漠型表型,并与癌症-免疫循环的不同设定点相关。EBV 与转录因子相互作用,引发 GPCR 相互作用组(GPCRome)重编程。趋化因子受体-1(CCR1)在恶性细胞和免疫抑制细胞上的表达增强,调节了微环境中的病毒-癌症相互作用。治疗性靶向 CCR1 在 NKTCL 类器官中显示出有前景的疗效,包括 EBV 清除、T 细胞激活和淋巴瘤细胞杀伤。
总之,我们的研究识别了一种此前未知的 GPCR 介导的恶性进展,并将病毒分子的传感器转化为 EBV 特异性抗癌治疗。
Epstein-Barr virus (EBV) is the oncogenic driver of multiple cancers.
However, the underlying mechanism of virus-cancer immunological interaction during disease pathogenesis remains largely elusive.
Here we reported the first comprehensive proteogenomic characterization of natural killer/T-cell lymphoma (NKTCL), a representative disease model to study EBV-induced lymphomagenesis, incorporating genomic, transcriptomic, and in-depth proteomic data.
Our multi-omics analysis of NKTCL revealed that EBV gene pattern correlated with immune-related oncogenic signaling. Single-cell transcriptome further delineated the tumor microenvironment as immune-inflamed, -deficient, and -desert phenotypes, in association with different setpoints of cancer-immunity cycle. EBV interacted with transcriptional factors to provoke GPCR interactome (GPCRome) reprogramming.
Enhanced expression of chemokine receptor-1 (CCR1) on malignant and immunosuppressive cells modulated virus-cancer interaction on microenvironment. Therapeutic targeting CCR1 showed promising efficacy with EBV eradication, T-cell activation, and lymphoma cell killing in NKTCL organoid. Collectively, our study identified a previously unknown GPCR-mediated malignant progression and translated sensors of viral molecules into EBV-specific anti-cancer therapeutics.
MEMBER ACCOUNT
登录成功会直接打开下一页。